Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.07.23.212357: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Mice and immunization: All the animal experiments were reviewed and approved by UH IACUC. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Female, 7-9 week-old BALB/c mice were purchased from Charles River Laboratories. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources ELISA: Anti-S protein antibody titers in serum or other biological fluids were determined using ELISA. ELISA: Anti-S proteinsuggested: NoneAnti-Ssuggested: NoneWe detected the captured antibodies by HRP-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories, 1 in 5,000; PA, USA), anti-mouse IgA … SciScore for 10.1101/2020.07.23.212357: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Mice and immunization: All the animal experiments were reviewed and approved by UH IACUC. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Female, 7-9 week-old BALB/c mice were purchased from Charles River Laboratories. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources ELISA: Anti-S protein antibody titers in serum or other biological fluids were determined using ELISA. ELISA: Anti-S proteinsuggested: NoneAnti-Ssuggested: NoneWe detected the captured antibodies by HRP-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories, 1 in 5,000; PA, USA), anti-mouse IgA (Bethyl Laboratories, 1 in 10,000; TX, USA) and detection antibody against mouse IgA (1 in 250) from the mouse total IgA ELISA kit from Invitrogen (CA, USA). anti-mouse IgGsuggested: Noneanti-mouse IgAsuggested: Nonetotal IgAsuggested: NoneExperimental Models: Cell Lines Sentences Resources Cell lines and plasmids: 293T cells stably expressing SARS-CoV-2 receptor human angiotensin-converting enzyme II (ACE2) and plasma membrane-associated type II transmembrane serine protease, TMPRSS2 (293 T/ACE2-TMPRSS2) were a generous gift from Dr. Siyan Ding (Washington University School of Medicine, St. Louis, MO, USA)36. 293Tsuggested: NoneExperimental Models: Organisms/Strains Sentences Resources Female, 7-9 week-old BALB/c mice were purchased from Charles River Laboratories. BALB/csuggested: RRID:IMSR_ORNL:BALB/cRl)Software and Algorithms Sentences Resources The 50% inhibitory dose (ID50) titers of NAbs were calculated using nonlinear regression (GraphPad Prism). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A fundamental limitation of all of these approaches is that they are not designed to elicit mucosal immunity. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses in the respiratory tract and the lung17,30,31. In the context of COVID19 existing data supports that initial infection in the nasal compartment promotes/facilitates subsequent seeding of the virus to the lung13. The ability of vaccines to thus promote immunity at the mucosal sites and specifically within the nasal compartment can prevent seeding of the initial reservoir and control human transmission. Intranasal vaccination is an attractive platform to elicit systemic and mucosal immunity. The fundamental challenge in intranasal vaccination is the ability to balance safety while ensuring immunogenicity leading to sterilizing immunity. Intranasal administration of live-attenuated vaccines in humans is hampered by concerns of safety32 and the use of the adenovirus vectored vaccines can be hampered by the presence of pre-existing immunity33. Subunit vaccines are attractive candidates that do not suffer from these drawbacks. However, the ability of subunit vaccines to elicit potent and sterilizing immune responses is critically dependent on the choice of appropriate adjuvants. We demonstrate that STINGa encapsulated in liposomes can function as potent adjuvants. A single intranasal immunization with protein S and the adjuva...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
